Luis J. Montaner

This study shows antigen stimulation can reactivate HIV-1 proviruses integrated in repressive chromatin, suggesting deeper latency may contribute to viral rebound.

This study shows targeting the LxCxE cleft pocket of Rb in M2 macrophages inhibits ovarian cancer progression by reducing immunosuppressive TAMs and enhancing T cell infiltration.

The paper identifies BACH2-driven tissue-resident memory programs in gut CD4+ T cells as a mechanism promoting HIV-1 persistence and suggests BACH2 as a therapeutic target.

HIV-1 viremia not suppressed by effective ART can be caused by proviruses in CD4+ T cells reactive to autologous antigens.

This study shows that Mukungulu, an African medicinal plant extract, effectively reverses HIV-1 latency in humanized mice and human cells, outperforming standard controls.

This study identifies Retinol Binding Protein 4 (RBP4) as a natural activator of latent HIV-1 through JAK/STAT5 and JNK pathways, offering a new strategy for reactivating viral reservoirs.

This study modifies NK cells to express CD64 and pre-load them with HIV-specific BNAbs, enhancing their ability to target HIV-infected CD4+ T cells via ADCC.

This paper introduces a microplate reader-based method to detect HIV latency reversal in J-Lat cells without flow cytometry, identifying new latency-reversing agents.

The paper shows that cognate antigen engagement in CD4+ T cells on long-term ART increases HIV-1 transcription through T cell activation, suggesting a role in viral rebound.

The paper isolates and characterizes neutralizing anti-interferon-alpha and anti-interferon-beta antibodies from human patients, showing their specificity and potential therapeutic applications.